ClinicalTrials.gg
RecruitingNCT07406126YRENEUpdated Nov 12, 2026

Yttrium-90 Radioembolization Neoadjuvant Therapy With Immune Marker Profiling and Dosimetry for Potentially Resectable Patients With Colorectal Liver Metastases

An observational study in Colorectal Liver Metastases (CRCLM) and Unresectable Colorectal Liver Metastases, sponsored by Fernando Gómez Muñoz. Recruiting at 5 sites in Spain. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Fernando Gómez Muñoz · Observational

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 3 months later.
Updated Nov 12, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
30
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 415 studies in Neoplasm Metastasis with a site in Spain — 79 open to participants now, 144 under way, 43 of them phase 3. Neoplasm Metastasis · Spain.

Planned enrollment
19th of 20
30 · median 454
Started
2026
with 12 others
Observational
20 of 415
9 open now
Primary completion
2028-07
later than 105 of 143 live
Registered
406th of 415
by date

Among the 415 studies in Neoplasm Metastasis with a site in Spain, this one is the 19th largest by planned enrollment of the 20 observational ones that give a count, is one of 13 that started in 2026, is one of 20 observational ones, reaches primary completion later than 105 of the 143 other live ones, and was the 406th registered.

Neoplasm Metastasis

4,052 studies on the registry are indexed under Neoplasm Metastasis; 891 are open to participants now.

Browse Neoplasm Metastasis studies →

Open to participants now

79 of the 415 studies in Neoplasm Metastasis with a site in Spain are open now. Recruiting first, the newest first:

73 more — sign in →

All 79 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 692 Neoplasm Metastasis studies recruiting now, 539 (78%) set no upper age limit and 96 (14%) stop at 75 or younger; 47 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 415 studies in Neoplasm Metastasis with a site in Spain, or all of them as a file.
02

Study summary

This is a observational, prospective, single arm, proof of concept study to assess safety, feasibility, and potential efficacy of combining Yttrium-90 transarterial radioembolization(TARE) with standard systemic therapy in clinical practice for potentially resectable patients with colorectal liver metastases (CRLM). Alternatively, resectability will also be evaluated. The investigators hypothesize that by applying this approach, higher local control and resection rates can be achieved (typically below 13% for patients who are initially deemed unresectable). Additionally, this treatment option is expected to help delay or reduce the need for (a switch in) systemic treatment and eventually improve survival in patients with liver metastases that are not resectable. All studies reporting the results of TARE at ablative doses are retrospective cohort studies or cases series. Prospective data is needed to expand the indications and reimbursement of radioembolization.

Other objectives of the study are:

  • To calculate the resection rate in patients undergoing the combined approach.
  • To evaluate immune markers in peripheral blood and resected metastases.
  • To formulate the first concept of an algorithm, enable to deliver personalized AI assisted dosimetry.
  • To assess potential role of circulating tumor DNA (ctDNA) in evaluation of patient prognosis and follow up.
  • To determine the grade of necrosis at the time of resection and correlate with the absorbed dose.
03

Conditions studied

  • Colorectal Liver Metastases (CRCLM)
  • Unresectable Colorectal Liver Metastases

Browse trials for

Keywords

  • Unresectable Colorectal Liver Metastases
  • Potentially resectable patient
  • neoadjuvant therapy
  • Immune Marker Profiling
  • circulating tumor DNA
  • personalized dosimetry approach
  • Insufficient future liver remnant
  • Observational
  • multicenter
  • prospective
  • YRENE
  • TARE
  • TheraSphere®
  • Yttrium-90
  • Transarterial Radioembolization
  • primary colon adenocarcinoma
  • primary rectum adenocarcinoma
  • Unfavourable tumor location
  • metastatic disease
  • FOLFOX 6
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients (N = 30) with insufficient FLR and patients with unfavorable lesion location, size and/ or number, requiring downsizing of metastases in order to achieve R0 resection will be discussed at the respective local multidisciplinary teams (MDT) meetings. Patients can be included if they are found suitable for TARE and surgery based on a liver MRI, contrast enhanced CT or PET-CT and clinical and laboratory results. Patients are allowed to undergo other local liver treatments (e.g. ablation) in combination with TARE, as long as all liver metastasis are locally treated to achieve R0 resection. Patients are not allowed to use systemic chemotherapy two weeks prior and two weeks post TARE. Target therapies have to be stopped at least 4 weeks prior to TARE.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed primary adenocarcinoma of the colon or rectum
  • Potentially resectable colorectal liver , with limiting factors for resection including:

    1. Insufficient future liver remnant.
    2. Unfavorable tumor location (e.g. involvement of a major vessel and/or bile duct)/ large size and/ or number of lesions, which limit resection with R0 margins and requires downsizing of the metastases
  • No or limited extrahepatic metastatic disease (limited extrahepatic disease should be amenable to eradicate with locoregional therapies as per multidisciplinary discussion of surgeons, radiation oncologists and interventional radiologists)
  • Patient should match standard 90Y radioembolization inclusion criteria:

    1. Signed ;
    2. Age ≥ 18 years;
    3. (ECOG) performance status 0-1;
    4. of ≥ 3 months;
    5. Measurable target tumors in the liver according to 1.1
  • Laboratory parameters: >45/mL/min/1.73 m2; albumin > 3.0 g/dl, normal (unless Gilbert syndrome); aminotransferase (ALAT/ASAT) \<3.0

Exclusion criteria

Exclusion Criteria:

  • ≤3 months
  • Patient initially eligible for surgery or thermal ablation of the liver
  • Progressive extra-hepatic disease
  • Active extra-hepatic disease that cannot be treated
  • Life-threatening extra-hepatic disease (i.e. dialysis, unresolved diarrhea, serious unresolved infections (, , etc.))
  • Uncorrectable coagulopathy
  • for angiography or MRI
  • Significant toxicities due to prior cancer therapy that have not resolved before the initiation of the study; if the investigator determines that the continuing complication will compromise the safe treatment of the patient
  • Any surgical contraindication
  • Ascites
  • Expected difficulties for safe execution of TARE based on pretreatment Tc99m-MAA imaging, including;
  • Flow to extra-hepatic vessels not correctable by reposition of catheter or embolization Uncorrectable estimated dose to the lungs >30Gy in a single administration or >50Gy cumulatively
  • Uncorrectable estimated dose to the untreated liver of >70Gy
  • Estimated average dose to the viable tumor volume \<200Gy
  • Prior liver radiotherapy
  • Severe portal hypertension
  • Second primary within the past 5 years, other that adequately treated non-melanoma skin cancer, carcinoma in situ of any organ or second primary colorectal cancer
  • Unresectable primary tumor in situ;
  • Other serious comorbidity or any other condition, that renders patients unsuitable for the study treatment
  • Pregnancy, lactation or refusal to use adequate measures
  • History of allergic reaction to any components of the treatment that cannot be medically corrected.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
30 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Interventions

  • ProcedureYttrium-90 Radioembolization with standard systemic therapy

    Yttrium-90 microspheres are administered through the hepatic artery which supplies blood to tumor tissue (the portal vein supplies blood to the normal hepatic tissue). The microspheres are trapped in the vasculature of the tumor due to arteriolar capillary blockage where they exert a local radiotherapeutic effect. In clinical use, the glass microspheres remain permanently trapped in the vasculature where the isotope decays to infinity leaving background radiation with no therapeutic value. This procedure is combined with standard systemic therapy per routine clinical practice.

06

What researchers measure

Primary outcomes

  1. Monitoring for adverse events related to the procedure.

    Evaluate the safety of combining neoadjuvant ablative dose 90Y radioembolization with standard systemic therapy in patients with CRLM. Safety assessments will include monitoring for adverse events related to the procedure.

    Time frame: From 90Y radioembolization (week 2-4) to the end of study at 30 weeks

  2. Evaluate the safety related to the procedure by measuring changes in Liver function values in blood.

    To evaluate hepatic safety after neoadjuvant ablative-dose Yttrium-90 radioembolization combined with standard systemic therapy in patients with CRLM changes in laboratory biomarkers will be compared with baseline values and subsequent assessments. Biomarkers and Units of Measure: \- Liver Function Markers: Bilirubin (mg/dL), Albumin (g/dL), Aspartate Aminotransferase (AST) (U/L), Alanine Aminotransferase (ALT) (U/L), Gamma-Glutamyl Transferase (GGT) (U/L), Alkaline Phosphatase (FA) (U/L), Cholinesterase (ChE) (U/L), Lactate Dehydrogenase (LDH) (U/L)

    Time frame: From 90Y radioembolization (week 2-4) to the end of study at 30 weeks

  3. Evaluate the safety related to the procedure by measuring changes in Liver function values in blood.

    To evaluate hepatic safety after neoadjuvant ablative-dose Yttrium-90 radioembolization combined with standard systemic therapy in patients with CRLM changes in laboratory biomarkers will be compared with baseline values and subsequent assessments. Biomarkers and Units of Measure: Inflammatory Marker: C-reactive protein (CRP) (mg/L) Renal Function Marker: Creatinine (mg/dL)

    Time frame: From 90Y radioembolization (week 2-4) to the end of study at 30 weeks

  4. Evaluate the safety related to the procedure by measuring changes in Liver function values in blood.

    To evaluate hepatic safety after neoadjuvant ablative-dose Yttrium-90 radioembolization combined with standard systemic therapy in patients with CRLM changes in laboratory biomarkers will be compared with baseline values and subsequent assessments. Biomarkers and Units of Measure: Composite Liver Function Scores: Albumin-Bilirubin (ALBI) score (unitless), Albumin-Bilirubin (ALBI) grade (ordinal scale)

    Time frame: From 90Y radioembolization (week 2-4) to the end of study at 30 weeks

  5. Evaluate the safety related to the procedure by measuring changes in tumor markers in blood.

    Evaluate the safety of combining neoadjuvant ablative dose 90Y radioembolization with standard systemic therapy in patients with CRLM by assessing tumor markers in blood: Carcinoembryonic antigen (CEA) and CA 19-9.

    Time frame: From 90Y radioembolization (week 2-4) to the end of study at 30 weeks

  6. Evaluate the quality of Life After Liver Resection Assessed by FACT-C (Version 4) Following 90Y Radioembolization

    Evaluate the safety of combining neoadjuvant ablative dose 90Y radioembolization with standard systemic therapy in patients with CRLM. Safety assessments will include assessing overall well-being of the patients focus on quality of life after liver resection. Outcome Measure: Change in Functional Assessment of Cancer Therapy-Colorectal (FACT-C, Version 4) total score from baseline to 30 weeks. The FACT-C (Version 4) total score and each subscale will be analyzed as independent measures to evaluate longitudinal changes in overall well-being and postoperative recovery after liver resection, characterizing treatment-related safety and tolerability. Quality-of-Life Instrument: Functional Assessment of Cancer Therapy-Colorectal (FACT-C, Version 4): Total score and subscale scores (Physical Well-Being, Social/Family Well-Being, Emotional Well-Being, Functional Well-Being, and Colorectal Cancer Subscale), reported according to standard scoring guidelines.

    Time frame: From 90Y radioembolization (week 2-4) to the end of study at 30 weeks

  7. Evaluate the efficacy of the procedure by tumor response rate assessed by means of RECIST 1.1

    Efficacy assessments will include tumor response rate assessed by means of RECIST 1.1. Baseline efficacy imaging scans will be conducted during the screening phase. Efficacy assessment scans will follow standard-of-care clinical management guidelines, occurring every 8 weeks (with a variance of +/- 1 week) post-inclusion until resection or until progression.

    Time frame: From week 0 to resection, progression or week 26-28

  8. Evaluate the efficacy of the procedure: pathologic response assessment on the resected specimens.

    Efficacy assessments will include tumor response rate assessed by means of RECIST 1.1. It will be of capital interest the pathologic response assessment on the resected specimens.

    Time frame: From week 0 to resection, progression or week 26-28

Secondary outcomes

  1. Resection rate in patients undergoing the combined approach

    It will indicate the percentage of patients who ultimately proceed to surgical resection of their liver metastases after receiving TARE as part of the neoadjuvant therapy. The decision of resection will be taken in the respective multidisciplinary meetings of each participating center.

    Time frame: week 18-20 and week 26-28

  2. Cellular population quantification on peripheral blood samples: leukocytes, neutrophils, lymphocytes, monocytes, eosinophils and basophils.

    Microbial fuel cell procedure will be performed on peripheral blood samples within the first 24-36 hours after collection. Bulk lysis technique will be done with the aim to concentrate leukocytes and, later, to detect minority populations. The quantification of each population will be performed in percentage and in absolute count, estimating the cells per microliter from the leukocyte value obtained in the complete blood count (CBC). In fact, a CBC will be done obtaining the percentages and absolutes values of neutrophils, lymphocytes, monocytes, eosinophils and basophils. Neutrophil-to-lymphocyte and lymphocyte-to-monocyte ratios will be estimated.

    Time frame: Week 0, 6, 8 and 16

  3. Inflammatory interleukines IL-6, IL-10 and IFN-γ quantification:

    Cytokines IL6 and IL10 levels

    Time frame: Week 0, 6, 8 and 16

  4. Intratumoral T Cells Infiltration in biopsies and resected tumors.

    The density of each tumor-infiltrating immune cell (CD3 and CD8) will be assessed in biopsies and resected tumors.

    Time frame: week 0, week 18/20 and week 26/28

  5. PERSONALIZED AI ASSISTED DOSIMETRY evaluation

    AI assisted dosimetry will be evaluated by the creation of a predictive model to assess treatment outcome based on planned and post-treatment high precision dose estimates. A prediction model based on corrected planning SPECT/CT and post-treatment PET/CT.

    Time frame: week 0 to 26-28

  6. ctDNA analysis: Identification of genetic alterations and circulating tumor DNA (ctDNA) monitoring through digital droplet PCR

    Sample collection and Nucleic acid isolation will be performed by means of Formalin-fixed paraffin embedded (FFPE) tumor biopsies (metastases). Two 10 mL Cell-Free DNA BCT ® CE (Streck) tubes of peripheral blood will be extracted for liquid biopsy studies. In FFPE tumour by NGS colorectal cancer cells are characterized by the acquisition of molecular alterations responsible for tumor development and progression. Digital droplet PCR (ddPCR) has emerged as an ultra-sensitive approach with various applications in the molecular diagnosis of tumors especially in liquid biopsy studies. KRAS, NRAS and BRAF mutation detection will be carried out.

    Time frame: week 6, 8, 12, 16, 22 and 30

  7. Macroscopic determination of the grade of necrosis

    the grade of necrosis will be analyzed through Histochemical staining of histological samples: standard hematoxylin-eosin staining. Staining of non-tumor liver with at least: Masson's trichrome and reticulin.

    Time frame: week 18/20 and week 26/28.

  8. Determination of the grade of necrosis: Microscopic study.

    The Microscopic report will include the number of nodules, size, distance to margin in mm, tumor regression grade and the lesions observed in the non-tumor liver parenchyma in resected tumors. With the presence or absence of viable tumor cells, it is advisable to report on the presence or absence of: Fibrosis, Necrosis, specifying whether it is of the normal or infarct-type and mucous extracellular.

    Time frame: week 18/20 and week 26/28.

  9. Evaluation of Post-treatment liver damage: Microscopic study

    Post-treatment liver damage: Presence and severity of steatosis, steatohepatitis and lesions related to the sinusoidal obstruction syndrome will be reported.

    Time frame: week 18/20 and week 26/28.

07

Study locations

2 of 5 sites recruiting
08

References and documents

Publications

  • Alsultan AA, van Roekel C, Barentsz MW, Smits MLJ, Kunnen B, Koopman M, Braat AJAT, Bruijnen RCG, de Keizer B, Lam MGEH. Dose-Response and Dose-Toxicity Relationships for Glass 90Y Radioembolization in Patients with Liver Metastases from Colorectal Cancer. J Nucl Med. 2021 Nov;62(11):1616-1623. doi: 10.2967/jnumed.120.255745. Epub 2021 Mar 19. PubMed 33741643 ↗
  • Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG 2nd, Herrmann K, Brown E, Zuckerman D, Wilson G, Kim TY, Weaver A, Ross P, Harris WP, Graham J, Mills J, Yubero Esteban A, Johnson MS, Sofocleous CT, Padia SA, Lewandowski RJ, Garin E, Sinclair P, Salem R; EPOCH Investigators. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. J Clin Oncol. 2021 Dec 10;39(35):3897-3907. doi: 10.1200/JCO.21.01839. Epub 2021 Sep 20. PubMed 34541864 ↗
  • Torkian P, Haghshomar M, Farsad K, Wallace S, Golzarian J, Young SJ. Cancer Immunology: Impact of Radioembolization of Hepatocellular Carcinoma on Immune Response Modulation. AJR Am J Roentgenol. 2023 Jun;220(6):863-872. doi: 10.2214/AJR.22.28800. Epub 2023 Feb 8. PubMed 36752368 ↗
  • Garin E, Tselikas L, Guiu B, Chalaye J, Edeline J, de Baere T, Assenat E, Tacher V, Robert C, Terroir-Cassou-Mounat M, Mariano-Goulart D, Amaddeo G, Palard X, Hollebecque A, Kafrouni M, Regnault H, Boudjema K, Grimaldi S, Fourcade M, Kobeiter H, Vibert E, Le Sourd S, Piron L, Sommacale D, Laffont S, Campillo-Gimenez B, Rolland Y; DOSISPHERE-01 Study Group. Personalised versus standard dosimetry approach of selective internal radiation therapy in patients with locally advanced hepatocellular carcinoma (DOSISPHERE-01): a randomised, multicentre, open-label phase 2 trial. Lancet Gastroenterol Hepatol. 2021 Jan;6(1):17-29. doi: 10.1016/S2468-1253(20)30290-9. Epub 2020 Nov 7. PubMed 33166497 ↗
  • Simmonds PC, Primrose JN, Colquitt JL, Garden OJ, Poston GJ, Rees M. Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies. Br J Cancer. 2006 Apr 10;94(7):982-99. doi: 10.1038/sj.bjc.6603033. PubMed 16538219 ↗
  • De Greef K, Rolfo C, Russo A, Chapelle T, Bronte G, Passiglia F, Coelho A, Papadimitriou K, Peeters M. Multisciplinary management of patients with liver metastasis from colorectal cancer. World J Gastroenterol. 2016 Aug 28;22(32):7215-25. doi: 10.3748/wjg.v22.i32.7215. PubMed 27621569 ↗

Individual participant data

Plan to share: Yes — De-identified individual participant data underlying the published results will be shared with qualified researchers upon reasonable request. Data will be available after publication for a period of 5 years. Requests should be directed to GIBI230@iislafe.es. Access will be provided after approval of a proposal and execution of a data use agreement.

Time frame: Data will be available after publication for a period of 5 years.

Access criteria: Qualified researchers upon reasonable request directed to GIBI230@iislafe.es.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for Jul 2028, 23 months after the start.

Of 211 non-industry observational studies under Neoplasm Metastasis, half reached primary completion within 74 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 172. This study's planned 23 months is below that.

Counting every sponsor, half of 242 studies reached it within 66 months; a quarter within 35 and three quarters within 172.

Start moved once since we started tracking on Sep 25, 2026: Feb 2026 → Aug 2026, on Nov 12, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Dec 4, 2025
First posted
Feb 12, 2026
StartActual
Aug 6, 2026was Feb 2026
Primary completionEst.
Jul 2028
CompletionEst.
Jul 2028
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Nov 12, 2026
Sites
5 sites changed recruiting status (3 now not yet recruiting, 2 now recruiting)
Show 5 sites
  • Hospital Universitario de Navarra · Pamplona, Spainno status→Not yet recruiting
  • Hospital Provincial de Castellón · Castelló, Spainno status→Recruiting
  • Hospital Universitario Virgen de las Nieves · Granada, Spainno status→Not yet recruiting
  • Hospital Universitario Ramón y Cajal · Madrid, Spainno status→Not yet recruiting
  • Hospital Universitario y Politécnico la Fe · Valencia, Spainno status→Recruiting
Nov 12, 2026
Start date
Feb 2026→Aug 6, 2026 (actual)
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Not yet recruiting→Recruiting
    5 sites changed recruiting status (3 now not yet recruiting, 2 now recruiting)
    Show 5 sites
    • Hospital Universitario de Navarra · Pamplona, Spainno status→Not yet recruiting
    • Hospital Provincial de Castellón · Castelló, Spainno status→Recruiting
    • Hospital Universitario Virgen de las Nieves · Granada, Spainno status→Not yet recruiting
    • Hospital Universitario Ramón y Cajal · Madrid, Spainno status→Not yet recruiting
    • Hospital Universitario y Politécnico la Fe · Valencia, Spainno status→Recruiting
    Start date Feb 2026→Aug 6, 2026 (now actual)

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07406126
Lead sponsor
Fernando Gómez Muñoz
Collaborators
Instituto de Investigacion Sanitaria La Fe, Boston Scientific International S.A.
Responsible party
Fernando Gómez Muñoz (Principal Investigator, MD, PhD, Instituto de Investigacion Sanitaria La Fe) — Sponsor-investigator
First posted
Feb 12, 2026
Start date
Aug 6, 2026
Primary completion
Jul 2028 (estimated)
Completion
Jul 2028 (estimated)
Last update
Nov 12, 2026

Study contacts

Fernando Gómez, MD PhD
Contact
gomez_fermun@gva.es
+34 628281300

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion